MacDonald A, Ferguson C, Rylance G, Morris A A M, Asplin D, Hall S K, Booth I W
The Children's Hospital, Steelhouse Lane, Birmingham B4 6NH, UK.
Arch Dis Child. 2003 Apr;88(4):327-9. doi: 10.1136/adc.88.4.327.
A phenylalanine-free amino acid based protein substitute is necessary to provide the major source of protein in phenylketonuria (PKU). Protein substitutes in PKU are usually given as drinks. These are unpalatable and compliance is often poor. Tablets containing a suitable mixture of phenylalanine-free amino acids (Aminogran Food Supplement, UCB) are now available.
To compare the effectiveness and acceptability of these tablets with conventional protein substitute drinks.
Twenty one subjects with PKU, aged 8-25 years, participated in a randomised crossover study. During one phase, subjects received at least 40% of their protein substitute requirements from the amino acid tablets and the rest from their usual protein substitute tablets. During the other phase, they received their usual protein substitute. Each period lasted 12 weeks. Blood phenylalanine concentrations were measured at least once every two weeks and other plasma amino acids were measured at the beginning, at crossover, and at the end of the study. The subjects kept a diary of all protein substitute taken.
Compliance appeared to be better with the new tablets than with patients' usual protein substitutes. Ninety per cent (18/20) recorded that they took the tablets as prescribed, compared with 65% (13/20) fully compliant with their usual protein substitute. Moreover, plasma phenyalanine was lower on the amino acid tablets, and the median difference in blood concentrations between the two groups was 46 micro mol/l (95% CI 14.8 to 89.0, p = 0.02). Tyrosine increased by a median of 16 micro mol/l daily on the amino acid tablets (95% CI 7.1 to 40.5, p = 0.01). Most subjects (70%) preferred incorporating the new tablets into their usual protein substitute regimen.
Amino acid tablets are an effective and relatively popular protein substitute in older children, teenagers, and adults with PKU.
对于苯丙酮尿症(PKU)患者而言,一种不含苯丙氨酸的氨基酸类蛋白质替代品是提供蛋白质主要来源所必需的。PKU患者的蛋白质替代品通常以饮品形式提供。这些饮品口感不佳,患者的依从性往往较差。现在已有含合适比例不含苯丙氨酸氨基酸混合物的片剂(Aminogran食品补充剂,优时比公司)可供使用。
比较这些片剂与传统蛋白质替代饮品的有效性和可接受性。
21名年龄在8至25岁的PKU患者参与了一项随机交叉研究。在一个阶段,受试者至少40%的蛋白质替代需求由氨基酸片剂提供,其余部分则来自其常用的蛋白质替代片剂。在另一阶段,他们使用其常用的蛋白质替代品。每个阶段持续12周。每两周至少测量一次血苯丙氨酸浓度,并在研究开始时、交叉点和结束时测量其他血浆氨基酸。受试者记录所服用的所有蛋白质替代品。
新片剂的依从性似乎优于患者常用的蛋白质替代品。90%(18/20)的患者记录他们按规定服用了片剂,相比之下,完全依从其常用蛋白质替代品的患者比例为65%(13/20)。此外,服用氨基酸片剂时血浆苯丙氨酸水平较低,两组血浓度的中位数差异为46微摩尔/升(95%可信区间14.8至89.0,p = 0.02)。服用氨基酸片剂时酪氨酸每天中位数增加16微摩尔/升(95%可信区间7.1至40.5,p = 0.01)。大多数受试者(70%)更喜欢将新片剂纳入其常用的蛋白质替代方案中。
氨基酸片剂对于年龄较大的儿童、青少年和成年PKU患者是一种有效且相对受欢迎的蛋白质替代品。